In preclinical models of type 2 diabetes and NAFLD, MPC inhibitors have shown promise in enhancing insulin sensitivity, reducing hepatic steatosis, and attenuating inflammatory responses. This evidence concerns the gene INS and type 2 diabetes mellitus.